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Background: Non-steroidal anti-inflammatory drugs (NSAIDs) frequently cause adverse drug reactions. Many studies
have shown that drugs which selectively inhibit the cyclooxygenase-2 enzyme (COX-2) are safe alternatives in the
majority of patients. However, hypersensitivity reactions to COX-2 inhibitors have been published. Hardly any data
are available regarding the safety of alternatives in case of COX-2 inhibitor hypersensitivity. We aimed to investigate
the tolerance to COX-2 inhibitors in patients with non-selective NSAID hypersensitivity. Furthermore, in COX-2
hypersensitive patients tolerance of a second COX-2 inhibitor was investigated.
Methods: We retrospectively analyzed 91 patients with proven non-selective NSAID hypersensitivity that
underwent oral challenges with a COX-2 inhibitor. Patients with intolerance to the first challenged COX-2 inhibitor
received a second challenge with a different COX-2 inhibitor.
Results: 19 out of 91 (21%) patients had a positive reaction to the first oral challenge with a COX-2 inhibitor. 14 of
them underwent a second challenge with a different COX-2 inhibitor and 12 (86%) did not react.
Conclusions: A relatively high percentage (21%) of the non-selective NSAID hypersensitive patients did not tolerate
a COX-2 inhibitor and oral challenge is advised prior to prescription of a COX-2 inhibitor. For the majority of
patients reacting to a COX-2 inhibitor an alternative can be found.
Keywords: COX-2, Drug hypersensitivity, Nonsteroidal anti-inflammatory drugs, Oral provocationBackground
NSAIDs (non-steroidal anti-inflammatory drugs) are
the most universally used analgesics and are responsible
for about 21-35% of all drug hypersensitivity reactions
[1-3]. Symptoms vary from cutaneous (urticaria and/or
angioedema) and respiratory (rhinitis and/or dyspnea) to
anaphylactic shock. The frequency of NSAID hypersensi-
tivity might be higher in patients with chronic spontaneous
urticaria, asthma [4-6] and mastocytosis [7]. The majority
of reactions (about 75%) are not caused by immunological
mechanisms (IgE or T-cell mediated), but by pharmaco-
logical inhibition of the cyclooxygenase-(COX) pathway
[8]. This is supported by the clinical observation that many
NSAID hypersensitive patients react to various NSAIDs of* Correspondence: h.rockmann@umcutrecht.nl
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reproduction in any medium, provided the orunrelated structure [5,6,9-11]. There are at least 2 isoforms
of COX; the constitutively expressed COX-1 enzyme takes
part in fundamental mechanisms of homeostasis, whereas
the inducible COX-2 enzyme mediates inflammation. The
therapeutic effects of NSAIDs are thought to be mainly re-
lated to the inhibition of COX-2, whereas COX-1 inhib-
ition seems to be more responsible for the adverse effects
[6,10]. For that reason selective COX-2 inhibitors have
been developed.
Therapeutic options to diagnose NSAID hypersensitivity
are still limited. Oral drug challenge (preferably placebo
controlled) is the gold standard in diagnosing NSAID
hypersensitivity [12,13].
Several studies have shown (partial) tolerability of
COX-2 inhibitors in patients with hypersensitivity to
non-selective NSAID and/or aspirin sensitive asthma
[14-16]. Weberstock et al. [15] reviewed 84 studies, 13 of
them described double-blind COX-2 inhibitor challenges.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sensitivity to COX-2 inhibitors, consisting of urticaria,
angioedema and/or rhinorrhea. Therefore, NSAIDs that
selectively inhibit COX-2 are assumed to be a safe alter-
native in the majority of non-selective NSAID hypersen-
sitive patients. A recent review by Asero [17] described
a wide variation in the percentage of COX-2 inhibitor
hypersensitivity up to 33%. Recently, Dona et al. [18]
described a high percentage of COX-2 inhibitor hyper-
sensitivity (25%) in patients with hypersensitivity to mul-
tiple non-selective NSAIDs and paracetamol. In the same
study, patients hypersensitive to multiple non-selective
NSAIDs, but tolerant to paracetamol showed only 6% of
COX-2 inhibitor hypersensitivity.
So far, tolerance of an alternative COX-2 inhibitor in
COX-2 hypersensitive patients has been hardly investi-
gated. A case-report of 2 patients with hypersensitivity to
numerous non-selective NSAIDs and a selective COX-2
inhibitor, described tolerance to a second COX-2 inhibi-
tor, celecoxib and etoricoxib respectively [19]. Quinones
Estevez [20] described a case series of 8 patients with
hypersensitivity to non-selective NSAIDs and selective
COX-2 inhibitors. Three of 5 patients that were chal-
lenged tolerated an alternative COX-2 inhibitor; celecoxib
or etoricoxib. A study comparing tolerance to different
COX-2 inhibitors (n = 37) (nimesulide, meloxicam and
rofecoxib) showed tolerance to meloxicam in 8 of 11
patients hypersensitive to nimesulide. The majority of
nimesulide hypersensitive patients (10/11) tolerated
rofecoxib [21].
The aim of this study was to assess the tolerance of a
first and, in case of intolerance, a second COX-2 inhibitor
in patients with hypersensitivity to non-selective NSAIDs
in a larger population.
Methods
Selection of patients
All patients (n = 91) with proven non-selective NSAID
hypersensitivity and oral challenge to a selective COX-2
inhibitor at the outpatient clinic of Allergology of the
University Medical Center Utrecht, from September 2002Table 1 Challenge protocols of culprit NSAIDs
Diclofenac Ibupro
Administration oral oral
Dose 1 (mg) 0.1 0.1
Dose 2 (mg); time interval (min) 1; 30 1; 30
Dose 3 (mg); time interval (min) 10; 30 10; 30
Dose 4 (mg); time interval (min) 25; 60 50; 30
Dose 5 (mg); time interval (min) 50; 60 100; 60
Dose 6 (mg); time interval (min) NA 200; 60
Legend: Min, minutes; NA, not applicable; (Since this study the dosages have beenuntil April 2012, were analyzed. NSAID hypersensitivity
was diagnosed, based on either a convincing unequivocal
patient history (n = 69), or a positive oral challenge with
the suspicious drug (n = 22). Challenge protocols are
shown in Table 1. The criteria for a convincing patient
history [22] were: 1. a time interval of a few minutes up
to a maximum of 5 hours between intake of the drug
and start of symptoms, 2. objective signs of urticaria,
angioedema, rhinitis, dyspnea and/or anaphylactic shock
(systolic BP <90 mm Hg or a >30 mm Hg drop). We an-
alyzed if patients had two or more reactions to the same
or distinct NSAID(s), reported either by challenge or by
history. We also analyzed usage and intolerance of para-
cetamol after reaction to the culprit drug documented in
patient history.
Study design
Sex, age, suspected NSAID(s) and co-morbidity data were
obtained, using patient files and, where necessary, tele-
phone calls to complete and confirm the data. The clin-
ical reaction patterns, the challenge with the culprit drug
and the outcome of challenge with COX-2 inhibitor were
assessed based on differentiated organ involvement: cuta-
neous (urticaria and/or angioedema), respiratory (rhinitis
and/or dyspnea) or anaphylactic shock. The Medical Ethics
Review Committee (METC) of UMC Utrecht agreed to
the study (METC-protocol number 12-438).
COX-2 inhibitor challenges
At first COX-2 inhibitor challenges were performed with
rofecoxib, until it was withdrawn from the market in
2003 (dosages: 1, 6.25, and 12.5 mg; interval 60 minutes).
After 2003, celecoxib was preferentially used for a first
challenge (dosages: 0.1, 1, 10, 20 mg at 30 minutes inter-
vals and 50 and 100 mg at 60 minutes intervals).
Etoricoxib was preferentially used for a second challenge
(dosages: 0.1, 1, 5, 10 mg at 30 minutes intervals and 30
and 60 mg at 60 minutes intervals). The time interval
between different oral challenges was 6–12 weeks.
The challenges were performed in a clinical setting,
equipped for resuscitation and monitoring of vital signs.fen Aspirin Naproxen Propyfenazon
oral oral oral
10 0.1 1
44; 30 1; 30 5; 30
117; 60 10; 30 25; 30
312; 60 50; 30 100; 60
500; 120 125; 30 250; 60
NA 250; 60 NA
revised and the dosage of 0.1 mg is removed.)
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lenge test was considered to be positive when objective
symptoms occurred, e.g. itching and erythema, urticaria,
angioedema, rhinoconjunctivitis, dyspnea, hypotension
or anaphylactic shock. If objective symptoms were present,
the challenge was stopped and the symptoms were treated
with antihistamines or prednisone. None of the patients re-
quired treatment with epinephrine.
Statistical analysis
Numeric results were expressed as mean ± standard de-
viation (SD). Nominal variables were expressed as per-
centage of the patients. The Statistical Package for Social
Sciences (SPSS) for Windows Version 15.0 was used to
analyze the data.
Results
Patient characteristics
91 patients with a diagnosis of non-selective NSAID
hypersensitivity were challenged with a first COX-2 in-
hibitor. The demographic and clinical characterizations
of the study group, as well as the drugs suspected to
cause a hypersensitivity reaction are shown in Table 2
and 3. Diagnosis of NSAID hypersensitivity was confirmed
by oral challenge with the culprit drug in 22 patients. In 69
patients, the history was highly suggestive and no oral chal-
lenges were performed. 44 (of 69) patients (63%) reported
repeated reactions to the same culprit drug. Of the 22
patients with a single reaction and without challenge to
the culprit drug 11 patients (50%) experienced anaphyl-
actic reactions. In 3 patients information about repeated
reactionswas missing.Table 2 Demographic and clinical features of the study
group
Variable Patients (n = 91)
Sex (male/female) n (%) 23/68 (25/75%)
Age (years) (mean ± SD) 51.9 ± 13.3
Reaction to 1 NSAID n (%) 71 (78%)
Reaction to various NSAIDs n (%) 20 (22%)
Reaction to paracetamol1 17 (18%)
Co-morbid disorders n (%)
- Chronic spontaneous urticaria 11 (12%)
- Asthma 9 (10%)
Diagnosed non-selective NSAID hypersensitivity n (%)
- Patient history; repeated reaction to the same culprit
drug
44 (48%)
- Patient history; no/unknown repeated reaction to
the same culprit drug
25 (28%)
- Oral challenge with the culprit drug 22 (24%)
1by patient history.Of the 91 patients, 9 (10%) suffered from concomitant
chronic asthma and 11 patients (12%) from concomi-
tant chronic spontaneous urticaria unrelated to the in-
take of NSAIDs. The majority of the patients (n = 71;
78%) reported a reaction to one NSAID, while 22%
(n = 20) reacted to several (2 or 3) non-selective NSAIDs.
Paracetamol was tolerated in 70 patients (79%) following
reaction to a NSAID. Information on paracetamol toler-
ance was missing in 4 patients. The most frequently
involved drug was diclofenac in 42 patients (46%).
Anaphylactic shock was the most frequent reaction type
reported in 32 subjects (35%), followed by angioedema in
23 subjects (25%). None of the patients suffered from as-
pirin sensitive asthma.
First COX-2 inhibitor challenges
In 77 patients (85%) celecoxib was given and in 13 pa-
tients (14%) rofecoxib. Etoricoxib was used in the first
challenge in only one patient. 19 patients (21%) had
a positive challenge to one of these COX-2 inhibitors.
Characteristics and symptoms of patients with a positive
first challenge are presented in Table 4 and 5. Three of
these COX-2 hypersensitive patients suffered from con-
comitant chronic spontaneous urticaria but were free of
urticarial symptoms for 6 weeks or more, before oral
challenge with the COX-2 inhibitor. In 14 of 19 patients
(74%) diagnosis of non selective NSAID hypersensitivity
was confirmed by challenge or repeated reaction to the
culprit NSAID. Eight of the 19 patients (42%) with a
positive challenge to a COX-2 inhibitor had a history of
hypersensitivity to multiple non-selective NSAIDs. Four
patients were intolerant to paracetamol. Ten patients
(16%) with unknown status of hypersensitivity to multiple
non-selective NSAIDs, reacted to a COX-2 inhibitor.
Second COX-2 inhibitor challenges
14 out of 19 patients with a positive first challenge to a
COX-2 inhibitor underwent a second challenge test with
a different COX-2 inhibitor (9 etoricoxib, 3 celecoxib
and 2 rofecoxib), while 5 patients declined. The second
provocation was positive in only 2 patients. Both pa-
tients presented with urticaria, generalized itch and dys-
pnoea following challenge with etoricoxib. One of them
had a history of hypersensitivity reactions to the non-
selective NSAIDs ibuprofen and naproxen together with
a past history of chronic spontaneous urticaria, but not
with asthma. The second patient had a history of hyper-
sensitivity reactions to diclofenac, without chronic spon-
taneous urticaria or asthma.
Discussion
In this retrospective study a relative high percentage of
21% COX-2 hypersensitivity was found in patients with
non-selective NSAID hypersensitivity. However, in COX-2
Table 3 Type of reaction to the suspected drugs according to patient history
Specific drug Type of reaction
Urticaria1 Angioedema2 Respiratory3 Anaphylaxis4 Total n (%)
Diclofenac 6 4 10 22 42 (46%)
Ibuprofen 2 5 4 4 15 (16%)
Naproxen 1 3 2 2 8 (9%)
Aspirin 0 2 2 0 4 (4%)
Propyfenazon 0 1 1 0 2 (2%)
Various NSAIDs 6 8 2 4 20 (22%)
Total 15 (16%) 23 (25%) 21 (23%) 32 (35%) 91 (100%)
1Presence of urticaria (without angioedema).
2Presence of angioedema (with or without urticaria).
3Presence of respiratory symptoms (rhinitis, dyspnea) (additional to urticaria and/or angioedema).
4Presence of hypotension <90 mmHg or >30 mmHg drop (additional to urticaria and/or angioedema).
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tor was found in the majority (86%) of patients.
There is a large variation (0% to 33%) in the percent-
age of COX-2 inhibitor hypersensitivity in patients with
NSAID hypersensitivity (17). Most studies describe low
percentages [15,21,23-37]. One study associated a high
percentages (25%) of hypersensitivity to etoricoxib with
paracetamol intolerance (compared to 6% in multiple
NSAID hypersensitivity without paracetamol intoler-
ance) [18]. In contrast, COX-2 inhibitor hypersensitivity
was not associated with paracetamol hypersensitivity in
our patient population.
Differences in study design may explain the variability
in the different studies. Many studies did not perform
oral challenges to confirm non selective NSAID hyper-
sensitivity [21,24,26,27,29,34,35,38]. This may have in-
duced a higher percentage of incorrect diagnosis of nonTable 4 Demographic and clinical features of patients
with positive first COX-2 inhibitor challenge
Variable Patients (n = 19)
Sex (male/female) n (%) 4/15 (21/79%)
Age (years) (mean ± SD) 53.2 ± 10.9
Reaction to 1 NSAID n (%) 12 (63%)
Reaction to various NSAIDs n (%) 7 (37%)
Reaction to paracetamol1 4 (21%)
Co-morbid disorders n (%)
- Chronic spontaneous urticaria 3 (16%)
- Asthma 4 (21%)
Diagnosed non-selective NSAID hypersensitivity n (%)
- Patient history; repeated reaction to the same culprit
drug
11 (58%)
- Patient history; no/unknown repeated reaction to
the same culprit drug
3 (15%)
- Oral challenge with the culprit drug 5 (26%)
1By patient history.selective NSAID hypersensitivity, especially since some
studies included patients with a long time interval, up to
72 hours, between intake of the culprit non selective
NSAID and onset of symptoms [26,29,33]. Incorrect
diagnosis of non selective NSAID hypersensitivity may
consequently lead to a lower estimate of the percentage
of COX-2 inhibitor hypersensitivity. The majority of pa-
tients in our study were also included based on a sug-
gestive history. However, we used strict criteria: only
patients with objective symptoms and within 5 hours
after intake were included. Furthermore, 53 (58%) pa-
tients had re-intake of the same culprit drug followed by
a similar hypersensitivity reaction, which strongly sup-
ports the diagnosis. 44 patients with a repeated reaction
did not underwent a challenge with the culprit drug. In
addition, the percentages of COX-2 hypersensitivity did
not differ between the patients diagnosed by careful his-
tory only versus those in which the diagnosis was con-
firmed by challenge.
Provocation with COX-2 inhibitors was open and not
placebo controlled. However, the challenges were only con-
sidered positive if the patient developed objective symp-
toms, in agreement with other studies [21,36]. Since we
performed this study, the challenged drug dosages have
been revised; the lowest dosage of 0.1 mg has appeared to
be unnecessary and has been removed from the protocol.
Another important factor that might influence the rate
of COX-2 inhibitor hypersensitivity is patient selection.
Patients in our population who previously reacted to nu-
merous non-selective NSAIDs had a higher rate (38%) of
reaction to COX-2 inhibitors than patients who reacted to
only one NSAID (16%). This is in line with Dona et al.,
analyzing patients with multiple NSAID hypersensitivity,
showing a generally high percentage of hypersensitivity to
etoricoxib [18]. Multiple NSAID reactivity was not known
in all patients. Therefore, the current classification of
EAACI/ENDA group [11] could not be applied to subdiv-
ide the study population.
Table 5 Clinical features and results of patients with positive first COX-2 inhibitor challenge
Patient
no.
Sex/
age
Co-morbid
disorders
Culprit
drug
Paracetamol
intolerance
Type of
reaction
Manner of
diagnosis
Reaction to oral COX-2 inhibitor challenges
First Second
Drug Reaction Drug Reaction
1 F/55 As diclofenac no U/A/Ana PH; repRX rofecoxib U/D nd
2 M/78 NS diclofenac no A/D/Ana C rofecoxib U nd
3 F/65 As multiple no U PH; repRX celecoxib U rofecoxib Neg
4 F/55 NS diclofenac no U/Ana C rofecoxib A celecoxib Neg
5 F/46 NS naproxen no A PH rofecoxib A celecoxib Neg
6 M/36 NS multiple yes U/A PH; repRX celecoxib U nd
7 F/35 NS multiple no U/A C etoricoxib U/A celecoxib Neg
8 F/51 As diclofenac no A/D PH; repRX celecoxib U/An/D/A nd
9 F/56 NS multiple yes A C, repRX celecoxib A rofecoxib Neg
10 F/50 NS naproxen no U/Ana PH; repRX celecoxib A etoricoxib Neg
11 F/59 NS naproxen no U/A PH; repRX celecoxib A etoricoxib Neg
12 F/46 NS diclofenac no U/A/D/Ana PH celecoxib A etoricoxib Neg
13 F/62 U multiple yes U/A PH; repRX celecoxib U nd
14 M/40 U ibuprofen yes U/A PH; repRX celecoxib U/D etoricoxib U/D
15 F/66 NS diclofenac no U/A/D/Ana PH; repRX celecoxib U/A etoricoxib Neg
16 F/63 NS multiple no U/A/ D PH; repRX celecoxib U/A etoricoxib Neg
17 F/53 NS diclofenac no U C celecoxib U/A etoricoxib U/A/D
18 F/46 A/U multiple no U/A PH; repRX celecoxib A etoricoxib Neg
19 M49 NS diclofenac no U/A PH celecoxib U/A etoricoxib Neg
Legend: F, female; M, male; NS, none specific; As, asthma; U, urticaria; A, angioedema (without weals); Ana, anaphylactic shock; D, dyspnea; PH, patient history;
repRx, repeated reaction to the same drug; C, challenge test; nd, not done; Neg, negative reaction. 2 patients with a positive challenge to a second COX-2 inhibitor
are highlighted in bold.
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drug, since acetylsalicylic acid (ASA) was the most
frequently reported culprit drug in many other studies
(21 - 100%) [14,21,23,25-27,29,30,33-36,39,40]. In our
study population, diclofenac, ibuprofen and naproxen
represented the most common culprit drugs with 46% ,
15% and 9% , respectively. Only 4 patients (4%) reported
a hypersensitivity reaction to ASA only. None of them
showed a reaction to a COX-2 inhibitor. Further studies
are needed to investigate the relation between the specific
culprit drug in non-selective NSAID hypersensitive pa-
tients and hypersensitivity to COX-2 inhibitors.
The frequency of chronic spontaneous urticaria (12%)
in our study group was comparable with previous litera-
ture (2.7-11%) [21,23,29,41] and cannot explain the high
percentage of COX- hypersensitivity. The frequency of
asthma in our study population was rather low, compared
to the literature [14,21,23,27,29,39]. Specific studies are
needed to investigate whether hypersensitivity to COX-2
inhibitors is dependent on these factors.
Interestingly, a second COX-2 inhibitor was tolerated
in the majority of challenged patients (86%). Of the pa-
tients with a second COX-2 inhibitor challenge, six hada history of reactions to multiple NSAIDs. However, five
of them tolerated the challenge with a second COX-2 in-
hibitor. This shows that patients who react to a particu-
lar COX-2 inhibitor, may be tolerant to another one.
This was also described in two small case-series [19,42].
Cimbollek et al. described two patients with multiple
NSAID hypersensitivity reacting to one COX-2 inhibitor
but tolerating another. Quinones-Estevez described 8
patients with multiple NSAID hypersensitivity of which
five were challenged with both celecoxib and etoricoxib.
Three patients reacted to only one of the drugs, while two
to both. In our study, etoricoxib was mainly used as a sec-
ondly challenged alternative COX-2 inhibitor, known to
have a much higher COX-2 selectivity than celecoxib [43].
This might explain the higher percentage of tolerance to
etoricoxib. However, advantage of etoricoxib over celecoxib
was not observed in case-series [19,20] or a recent review
analyzing COX-2 inhibitor hypersensitivity [17].
Our results in a large group of patients with NSAID
hypersensitivity and reaction to a specific COX-2 inhibi-
tor show that an alternative COX-2 inhibitor can be tol-
erated.Challenge with a second COX-2 inhibitor can be
recommended in these patients. So far, there seems no
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should be challenged first and which second.
Conclusions
In most patients with non-selective NSAID hypersensi-
tivity COX-2 inhibitors were safe. However, given the
relatively high percentage (21%) of positive challenges, it
is necessary to perform an oral challenge prior to pre-
scription. In case of hypersensitivity to a COX-2 inhibi-
tor, second challenges with a different COX-2 inhibitor
can provide an alternative. Further studies are needed to
define risk factors for COX-2 inhibitor hypersensitivity
in patients with non-selective NSAID hypersensitivity.
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